Oncopeptides Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Oncopeptides wird ein jährliches Gewinn- und Umsatzwachstum von 35.8% bzw. 92.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 65.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -152.6% betragen.

Wichtige Informationen

35.8%

Wachstumsrate der Gewinne

65.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	45.5%
Wachstumsrate der Einnahmen	92.1%
Zukünftige Eigenkapitalrendite	-152.6%
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued

Jun 18

Gewinn- und Umsatzwachstumsprognosen

OM:ONCO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	247	-106	-44	-108	3
12/31/2025	117	-205	-150	-201	3
12/31/2024	35	-266	-264	-265	3
9/30/2024	27	-282	-245	-244	N/A
6/30/2024	21	-263	-172	-172	N/A
3/31/2024	39	-246	-258	-258	N/A
12/31/2023	35	-249	-280	-279	N/A
9/30/2023	30	-259	-304	-302	N/A
6/30/2023	27	-307	-317	-315	N/A
3/31/2023	9	-310	-346	-343	N/A
12/31/2022	8	-338	-423	-421	N/A
9/30/2022	-14	-641	-790	-789	N/A
6/30/2022	41	-1,330	-1,055	-1,055	N/A
3/31/2022	99	-1,294	-1,296	-1,296	N/A
12/31/2021	118	-1,430	-1,517	-1,516	N/A
9/30/2021	140	-1,549	-1,444	-1,427	N/A
6/30/2021	86	-1,155	-1,449	-1,431	N/A
3/31/2021	19	-1,532	-1,388	-1,370	N/A
12/31/2020	N/A	-1,595	-1,314	-1,297	N/A
9/30/2020	N/A	-1,327	-1,159	-1,156	N/A
6/30/2020	N/A	-1,133	-1,026	-1,023	N/A
3/31/2020	N/A	-904	-863	-861	N/A
12/31/2019	N/A	-741	-693	-691	N/A
9/30/2019	N/A	-608	-583	-582	N/A
6/30/2019	N/A	-512	-469	-469	N/A
3/31/2019	N/A	-485	-436	-436	N/A
12/31/2018	N/A	-411	-334	-334	N/A
9/30/2018	N/A	-368	-272	-271	N/A
6/30/2018	N/A	-325	N/A	-262	N/A
3/31/2018	N/A	-248	N/A	-244	N/A
12/31/2017	N/A	-250	N/A	-271	N/A
9/30/2017	N/A	-243	N/A	-270	N/A
6/30/2017	N/A	-216	N/A	-211	N/A
3/31/2017	N/A	-172	N/A	-159	N/A
12/31/2016	N/A	-125	N/A	-104	N/A
12/31/2015	N/A	-62	N/A	-53	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ONCO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ONCO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ONCO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ONCODie Einnahmen des Unternehmens (92.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (0.06% pro Jahr).

Hohe Wachstumseinnahmen: ONCODie Einnahmen des Unternehmens (92.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ONCO wird voraussichtlich in 3 Jahren unrentabel sein.

Oncopeptides Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 19%, EPS upgraded

Consensus revenue estimates decrease by 34%, EPS upgraded

Price target decreased by 29% to kr4.33

Consensus revenue estimates fall by 11%

Consensus EPS estimates fall by 34%, revenue upgraded

Price target decreased by 7.2% to kr6.40

Recent updates

Consensus revenue estimates decrease by 19%, EPS upgraded

Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.45 loss in 3Q 2023)

New minor risk - Share price stability

Consensus revenue estimates decrease by 34%, EPS upgraded

Price target decreased by 29% to kr4.33

Second quarter 2024 earnings released: kr0.48 loss per share (vs kr0.60 loss in 2Q 2023)

Consensus revenue estimates fall by 11%

An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million.

An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued

Consensus EPS estimates fall by 34%, revenue upgraded

First quarter 2024 earnings released: kr0.75 loss per share (vs kr0.75 loss in 1Q 2023)

Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress

New major risk - Shareholder dilution

Price target decreased by 7.2% to kr6.40

Consensus EPS estimates fall by 38%

Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024

Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024

Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million.

Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely

New major risk - Financial position

Oncopeptides AB (publ), Annual General Meeting, May 22, 2024

Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines

Oncopeptides AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Oncopeptides Selects to Present Additional Data from Ocean Study

Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?

Oncopeptides AB (publ) to Report Q2, 2024 Results on Aug 14, 2024

Oncopeptides AB (publ) Announces the Nomination Committee

Oncopeptides AB (publ) to Report Q1, 2024 Results on May 03, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Final Results on Apr 22, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Oncopeptides AB (Publ) Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial Results

Consensus revenue estimates increase by 47%

Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial Officer

Oncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO Role

We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully

Holger Lembrér Will Leave Oncopeptides as Chief Financial Officer

Consensus revenue estimates decrease by 11%, EPS upgraded

No longer forecast to breakeven

Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Oncopeptides AB (publ) to Report Q2, 2023 Results on Aug 10, 2023

Full year 2022 earnings released: kr4.11 loss per share (vs kr19.00 loss in FY 2021)

Forecast to breakeven in 2024

Oncopeptides AB (Publ) Announces Chief Financial Officer Changes

Oncopeptides AB (publ) Announces Jakob Lindberg Assumes Chief Scientific Officer

Oncopeptides AB (Publ) Announces Executive Changes

Oncopeptides AB (publ) Announces Nomination Committee Appointments

Oncopeptides AB (publ) to Report Fiscal Year 2022 Final Results on Apr 25, 2023

Oncopeptides Provides Update on Pepaxto US Marketing Authorization

Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Price target decreased to kr22.50

Consensus revenue estimates fall by 76%

Insufficient new directors

Oncopeptides AB (Publ) Announces Pepaxti Has Been Granted Marketing Authorization in the Uk

Oncopeptides AB (Publ) Announces the Market Potential for Pepaxti in Europe

Forecast to breakeven in 2024

Oncopeptides AB (publ), Annual General Meeting, May 25, 2023

Oncopeptides AB (publ) Announces Data from the Phase 3 Lighthouse Study

Consensus revenue estimates fall by 30%

Oncopeptides AB (publ) Starts Commercialization of Pepaxti in Europe - Germany First Market

Consensus revenue estimates fall by 36%

Oncopeptides AB (publ) Provides Update from Meeting with Advisory Committee ODAC

Oncopeptides AB (Publ) Receives SEK 5 Million Grant for Nk-Cell Engager Project in Multiple Myeloma

European Commission Approves Oncopeptides' Pepaxti for the Treatment of Patients with Relapsed Refractory Multiple Myeloma

Consensus revenue estimates increase by 243%

Oncopeptides AB (Publ) Issues A Positive Opinion Recommending Full Approval of Oncopeptides Peti in Eu for Patients with Tr Triple Class Refractory Multiple Myeloma

Consensus revenue estimates increase by 89%

Oncopeptides AB (Publ) Announces That the European Medicines Agency´S Committee for Medicinal Products for Human Use

Price target increased to kr11.15

Consensus forecasts updated